Database for
Therapeutic Antibodies
Therapeutic Antibodies
| Entry ID | 147 |
| INN | Brentuximab vedotin |
| Status | Approved |
| Drug code(s) | SGN-35 |
| Brand name | Adcetris |
| mAb sequence source | mAb chimeric |
| General Molecular Category | ADC |
| Format, general category | Full length Ab conjugate |
| Format details | None |
| Isotype (Fc) | IgG1 |
| Light chain isotype | kappa |
| Linker | Valine-Citrulline, Cleavable linker |
| Ave. DAR | 4 |
| Conjugated/fused moiety | Tubulin inhibitor, Monomethyl auristatin E (MMAE) |
| Discovery method/technology | None |
| Target(s) | CD30 |
| Indications of clinical studies | Hodgkin's lymphoma, anaplastic large cell lymphoma, germ cell tumors, mesothelioma, lymphatic diseases, systemic lupus erythematosus |
| Primary therapeutic area | Cancer |
| Most advanced stage of development (global) | Approved EU, US, Japan, Australia |
| Status | Active |
| Start of clinical phase (IND filing or first Phase 1) | November 15, 2006 |
| Start of Phase 2 | February 15, 2009 |
| Start of Phase 3 | April 15, 2010 |
| Date BLA/NDA submitted to FDA | February 28, 2011 |
| Year of first approval (global) | 2011 |
| Date of first US approval | August 19, 2011 |
| INN, US product name | Brentuximab vedotin |
| US or EU approved indications | Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, Cutaneous T-Cell Lymphoma, treatment of adult patients with previously untreated stage III or IV classical Hodgkin lymphoma |
| Company | Seattle Genetics |
| Licensee/Partner | None |
| Comments about company or candidate | US orphan; Fast track |
| Full address of company | 21823 30Th Dr Se Bothell, WA 98021, United States North America United States of America https://www.sbir.gov/node/302736 |
Cysteine conjugated ADC
| Anticipated events | None |
| Factor(s) contributing to discontinuation | None |